10-Q: INVO Fertility Reports Q2 2026 Growth Amidst Financial Controls Concerns

INVO Fertility, Inc. (IVF) filed its Q2 2026 Form 10-Q, showing revenue growth driven by clinic acquisitions, but also highlighting ongoing liquidity concerns and material weaknesses in internal controls.

Summary

• INVO Fertility, Inc. reported its Q2 2026 results, showing an increase in revenue to $2.18 million for the quarter and $4.19 million for the six months ended June 30, 2026, up from $1.86 million and $3.50 million in the prior year periods, respectively.
• The company completed the acquisition of Family Beginnings P.C. in February 2026 and acquired 100% of HRCFG INVO, LLC in June 2026, contributing to revenue growth.
• Despite revenue increases, the company continues to face substantial doubt about its ability to continue as a going concern, necessitating future debt and/or equity financing.
• Material weaknesses in internal control over financial reporting were identified, primarily related to limited segregation of duties and inadequate accounting resources for complex transactions.
• The company reported a net income of $0.89 million for the three months ended June 30, 2026, a significant improvement from a net loss of $3.62 million in the prior year period, largely due to a gain on remeasurement of $2.45 million.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as cautiously optimistic. While revenue is growing and acquisitions are being integrated, the company continues to face significant going concern risks and material weaknesses in internal controls.

Positives

• Revenue increased by 18% to $2.18 million for the three months ended June 30, 2026, compared to $1.86 million in the prior year period.
• Revenue for the six months ended June 30, 2026, increased by 20% to $4.19 million, compared to $3.50 million in the prior year period.
• Successful completion of the Family Beginnings acquisition in February 2026 and the HRCFG acquisition in June 2026, integrating them into consolidated financial statements.
• Net income of $0.89 million for the three months ended June 30, 2026, a significant turnaround from a net loss of $3.62 million in the prior year period.
• A gain on remeasurement of $2.45 million was recognized in the current period, primarily related to the HRCFG acquisition.
• Cash position improved to $3.73 million as of June 30, 2026, from $2.08 million as of December 31, 2025.
• The company's stock price was not negatively impacted by Nasdaq delisting concerns, as it regained compliance on June 23, 2026.

Negatives

• Substantial doubt exists about the company's ability to continue as a going concern, requiring future financing that may not be available.
• Material weaknesses in internal control over financial reporting were identified, including limited segregation of duties and insufficient accounting resources.
• Selling, general, and administrative expenses increased by 9% to $4.1 million for the six months ended June 30, 2026.
• A loss of $3.79 million was recorded in the six months ended June 30, 2026, related to the change in fair value of warrant liability.
• The company reported a net loss of $4.65 million for the six months ended June 30, 2026.
• Negative working capital of $1.9 million as of June 30, 2026.

Risks

• The company's financial condition and need for additional capital raise substantial doubt about its ability to continue as a going concern.
• Limited operating history and a history of net operating losses require continued access to capital and clinic revenue growth to fund operations.
• The fertility and ART services industry is highly competitive.
• Growth strategy is dependent on identifying and successfully completing and integrating fertility clinic acquisitions.
• Reliance on a single third-party manufacturer for INVOcell production.
• Evolving state and federal laws on abortion and embryo personhood could impact the business.
• Material weaknesses in internal control over financial reporting could lead to misstatements in financial reports.
• Cybersecurity threats or data breaches involving sensitive patient health information pose a risk.

Future Outlook

The company expects its fertility operations to expand through organic growth and further acquisitions of profitable fertility clinics. The strategy aims to accelerate growth, build scale, and achieve profitability. The company also plans to continue developing the INVOcell technology and seeking new innovative technologies.

Management Comments

• "As we continue to build and grow the business, our primary focus has been strengthening the balance sheet, seeking out additional acquisition opportunities, and driving revenue within our existing operating clinics."
• "Until we can generate a sufficient amount of cash from operations, we will need to raise additional funding to meet our liquidity needs and to execute our business strategy."
• "The acquisition of profitable IVF clinics complements our efforts to build new INVO Centers, and we expect to continue this strategy to accelerate overall growth."

Industry Context

StockSavvy.ai notes that INVO Fertility operates in the growing global ART market, driven by increasing infertility rates and awareness. However, the market remains underserved due to cost and capacity barriers, which INVO's strategy of acquiring clinics and offering the INVOcell aims to address.

Comparison to Industry Standards

• The company's revenue growth of 18% for the quarter and 20% year-to-date is positive, but the company's continued net losses and going concern issues highlight challenges in achieving profitability compared to established, larger players in the ART market.
• The reported pregnancy success rates for the INVOcell procedure are stated to be equivalent to traditional IVF, which is a key benchmark in the industry.
• The company's strategy of acquiring established, profitable clinics like Wisconsin Fertility Institute and Family Beginnings is a common approach to gain market share and scale in the fragmented fertility services sector.

Legal Proceedings

• The company is not currently subject to any material legal proceedings, but could be subject to such matters from time to time.

Related Party Transactions

• The company has outstanding related party demand notes and convertible notes with JAG Multi Investments LLC, with extended maturity dates and modified conversion terms.
• The company issued a new warrant to JAG Multi Investments LLC in May 2026 as part of a note amendment.
• Demand promissory notes were issued to the CEO and an entity controlled by the Chief Business Officer in Q4 2022, with ongoing interest accrual and callable terms.

Stakeholder Impact

• Shareholders may see potential dilution from future equity financings and the AMPA, but also potential upside from revenue growth and acquisitions.
• Creditors may be concerned about the company's going concern status, though recent financing and revenue growth offer some reassurance.
• Employees are likely to be impacted by the company's growth strategy, which includes acquisitions and potential expansion.
• Customers (patients) may benefit from increased access to fertility treatments and potentially more affordable options through the INVOcell technology and clinic network.

Next Steps

• Continue to grow clinic revenue organically.
• Pursue additional profitable fertility clinic acquisitions.
• Seek additional debt and/or equity financing to meet liquidity needs.
• Continue to develop and market the INVOcell technology.
• Seek out additional innovative fertility-focused technologies for licensing or acquisition.

Key Dates

Recommendation

The company shows revenue growth and strategic acquisitions, which are positive. However, the persistent going concern issues, material weaknesses in internal controls, and reliance on future financing introduce significant risk. A 'hold' recommendation reflects a balance between the potential for recovery and the substantial uncertainties.

Keywords

Fertility Clinics, INVOcell, ART Services, Acquisition, Business Combination, Revenue Growth, Going Concern, Internal Controls